(Adds dropped word 'ended' in second paragraph)
Nov 4 (Reuters) - Regeneron Pharmaceuticals Inc reported a higher quarterly revenue on increased sales of itseye injection Eylea.
The biotechnology company's net profit fell to $79.7million, or 70 cents per share, in the third quarter ended Sept.30, from $141.3 million, or $1.25 per share, a year earlier.
Excluding special items, Regeneron earned $2.52 per share.
Revenue rose 21.6 percent to $725.8 million and includedcollaboration payments from French drugmaker Sanofi SA and German partner Bayer AG.
U.S. sales of Eylea rose 23 percent to $445 million. (Reporting by Natalie Grover in Bangalore; Editing by SavioD'Souza)
Nov 4 (Reuters) - Regeneron Pharmaceuticals Inc reported a higher quarterly revenue on increased sales of itseye injection Eylea.
The biotechnology company's net profit fell to $79.7million, or 70 cents per share, in the third quarter ended Sept.30, from $141.3 million, or $1.25 per share, a year earlier.
Excluding special items, Regeneron earned $2.52 per share.
Revenue rose 21.6 percent to $725.8 million and includedcollaboration payments from French drugmaker Sanofi SA and German partner Bayer AG.
U.S. sales of Eylea rose 23 percent to $445 million. (Reporting by Natalie Grover in Bangalore; Editing by SavioD'Souza)
via Smart Health Shop Forum http://ift.tt/1tDCrgo
No comments:
Post a Comment